Spots Global Cancer Trial Database for Identifying MSI Status From ctDNA in Chinese Patients With Refractory Advanced Solid Tumors

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Identifying MSI Status From ctDNA in Chinese Patients With Refractory Advanced Solid Tumors

Official Title: Identifying Microsatellite Instability Status From Circulating Tumor DNA in Chinese Patients With Refractory Advanced Solid Tumors: a Large Molecular Epidemiological Investigation

Study ID: NCT03596593

Conditions

Solid Tumor

Interventions

SPANOM (identifying MSI status from ctDNA)

Study Description

Brief Summary: This is a molecular epidemiological investigation aiming to identify microsatellite instability status from circulating tumor DNA in Chinese patients with refractory advanced solid tumors.

Detailed Description: This study is conducted in Chinese patients with advanced refractory metastatic solid tumors. A total of 8-10 mL of blood will be collected from eligible patients and used for extracting circulating tumor DNA. Blood-MSI status will be tested based on SPANOM technique developed by 3D Medicines Inc. Shanghai, China. Patients are encouraged to provide tissues collected from progressive disease for tissue-MSI testing (not required for inclusion).